Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
ESLA
#3526
Estrella Immunopharma, Inc. Common Stock
1.2
2
+0.83%
Secteur:
Base:
Devise de Profit:
Range quotidien
Range Annuel
Changement quotidien
+0.83%
Changement Mensuel
+10.91%
Evolution sur 6 mois
+29.79%
Changement Annuel
+25.77%
Clôture Précédente
1.2
1
Open
1.2
2
Bid
Ask
Low
1.2
2
High
1.2
2
Volume
1
Marchés
Actions des Marchés US
Soins de Santé
ESLA
Open full chart
Financials
Overview
Relevé
Statistics
Dividends
Quarterly
Annual
Value
2021
2022
2023
TTM
Key stats
Total common shares outstanding
5.85 M
2.33 M
35.2 M
—
Valuation ratios
Enterprise value
—
—
36.11 M
149.91 M
Price to earnings ratio
—
—
-4.07
-0.42
Price to sales ratio
—
—
7.93
—
Price to cash flow ratio
—
—
-1.86
-25.78
Price to book ratio
—
—
7.9
-12.16
Enterprise value to EBITDA ratio
—
—
—
—
Profitability ratios
Return on assets %
-0.01
-0.1
-1.64
-4.99
Return on equity %
0.25
0.44
-1.71
-1.98
Return on invested capital %
-2.2
-24.51
-557.25
361.44
Gross margin %
—
—
100
—
Operating margin %
—
—
-194.49
—
EBITDA margin %
—
—
—
—
Net margin %
—
—
-194.53
—
Liquidity ratios
Quick ratio
—
—
—
—
Current ratio
8.42
0.05
24.65
1.28
Inventory turnover
—
—
—
—
Asset turnover
—
—
0.53
—
Solvency ratios
Debt to assets ratio
—
—
—
—
Debt to equity ratio
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
Per share metrics
Operating cash flow per share
-0.27
-0.24
-0.59
-0.11
EBIT per share
—
—
—
—
EBITDA per share
—
—
—
—
Total debt per share
—
—
—
—
Cash per share
0.41
0.01
0.15
0.14
Net current asset value per share
0.52
0.01
0.16
0.18
Tangible book value per share
-0.85
-0.22
0.14
-0.48
Working capital per share
0.46
-0.23
0.16
-0.63
Book value per share
-0.85
-0.52
0.14
-0.48
Nouvelles
Estrella annonce un taux de réponse complète de 100% dans son essai sur le lymphome
Estrella reports 100% complete response rate in lymphoma trial
Estrella présentera des données de phase 1 sur sa thérapie cellulaire ciblant CD19
Estrella to present phase 1 data on CD19-targeted cell therapy
Estrella Immunopharma reçoit un avis du Nasdaq pour retard de son assemblée annuelle
Estrella Immunopharma receives Nasdaq notice for delayed annual meeting
Estrella Immunopharma clôture une offre directe enregistrée de 8 millions $
Estrella Immunopharma closes $8 million registered direct offering
Le titre de l’action Estrella Immunopharma chute après l’annonce d’une offre de 8 millions $
Estrella Immunopharma stock falls after announcing $8 million offering
Estrella Immunopharma lève 8 millions de dollars via une offre enregistrée
Estrella Immunopharma raises $8 million through registered offering